CNTB: Connect Biopharma Holdings Price to Sales
Connect Biopharma is implementing AI software and robotics for bioscreening. The price-to-sales valuation reflects the current market trend, where the value of 14.10 indicates the actual figure. The company attracts global biochemists with generous stock options while minimizing costs by outsourcing production and testing to third-party contractors. This approach ensures the scientific team remains flexible during the development of immune drugs.
Metric breakdowns and analytics for Connect Biopharma (CNTB)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Connect Biopharma|CNTB - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio connectbiopharm.com|CNTB - Company Aggregate Debts|Debts to Book Value Connect Pharma|CNTB - Company Long-Term Debts|Company Current Liabilities Connect Biopharma|Intermediate Liquidity Ratio connectbiopharm.com
- business earnings and investment ratios data:
CNTB - Net Income|Expected Net Income Connect Biopharma|CNTB - P/E Multiple|Future Price to Earnings connectbiopharm.com|CNTB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Connect Pharma|CNTB - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Connect Biopharma|CNTB - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months connectbiopharm.com|CNTB - Earnings growth in current year|Expected earnings per share trend next year Connect Biopharma
- total revenue and sales volume data:
General company analysis:CNTB - Connect Biopharma Holdings
Connect Biopharma (CNTB) is developing innovative drugs for the treatment of severe allergies, leveraging the success of clinical trials. The ratio of market capitalization to annual revenue allows for an assessment of the business value relative to its actual sales. By analyzing the price-to-sales ratio, an investor can identify pricing distortions and speculative deviations from fundamental value. The stability of this metric confirms the resilience of the business model and the medical community's confidence in the company's assets.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Protagonist Corp (PTGX) - Market Cap to Revenue|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Market Cap to Revenue Ratio ADPT (Adaptive Biotech)|Price-to-Revenue Ratio Celldex (CLDX)|Aurinia Corp - Market Cap to Revenue Ratio|P/S Multiple BCRX (BioCryst)|veratx.com (VERA) - Price to Sales|Dianthus Therapeutics, Inc. - P/S Multiple|Pharvaris NV (PHVS) - Market Cap to Revenue|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|TRML: Market Cap to Sales Volume|Market Cap to Revenue PGEN|PHAR: Market Capitalization-to-Revenue Ratio|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio, Inc.)|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Price-to-Revenue Coefficient Immunome Bio (IMNM)|GOSS - Price-to-Revenue Ratio|Price to Sales kalvista.com|Septerna (SEPN) - Price-to-Revenue Ratio|Price-to-Sales Ratio PVLA (Pieris Pharma)|SVRA (Savara Corp) - P/S Multiple|RIGL: Market Capitalization-to-Revenue Ratio|P/S Multiple ANAB|P/S Multiple astriatx.com (ATXS)|Price-to-Revenue Ratio enGene ENGN|Market Capitalization-to-Revenue Ratio RAPT|JBIO - Price-to-Revenue Ratio|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Revenue|KYTX: P/S Multiple|tizianalifesciences.com (TLSA) - P/S Multiple|CABA (Cabaletta Bio) - P/S Multiple|Market Cap to Revenue Ventyx Biosciences Inc. (VTYX)|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Avalo Therapeutics Inc - Market Cap to Revenue Ratio|Eledon Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume AGEN (agenusbio.com)|Climb Bio - P/S Multiple|ZURA: Price-to-Revenue Ratio|aTyr (ATYR) - Price-to-Revenue Ratio|Price-to-Sales Ratio ADAG (Adagene Inc.)|IMA (ImageneBio) - P/S Multiple|STTK: Market Capitalization-to-Revenue Ratio|P/S Multiple EQ|P/S Multiple immunic-therapeutics.com (IMUX)|Price-to-Revenue Ratio Atara Bio ATRA|Market Capitalization-to-Revenue Ratio IFRX|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|CELU: P/S Multiple|INmune Bio Inc (INMB) - P/S Multiple|Market Cap to Revenue BRNS|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|Price-to-Revenue Coefficient akaritx.com|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Market Cap to Revenue|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO (iBio, Inc.) - Market Cap to Revenue|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Ratio BOLT (Bolt Bio)|P/S Multiple HCWB|APVO - Price to Sales|P/S Multiple AIM (AIM ImmunoTech Inc.)|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|Price to Sales XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|P/S Multiple CALI|AFMD - Price to Sales|P/S Multiple ALLK (Allakos)|HOOK - Market Cap to Revenue|IGMS: Market Cap to Revenue|iteostherapeutics.com - Market Cap to Sales Volume|OCEA (Ocean Biomedical) - Market Cap to Revenue|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
